Overview

* Amedisys ( AMED ) Q2 net service revenue rises to $621.9 mln from $591.2 mln

* Adjusted EPS for Q2 beats estimates, reaching $1.54, per LSEG data

* Adjusted EBITDA of $80.8 mln surpasses analyst expectations, per LSEG data

Result Drivers

* MERGER EXPENSES - Higher merger-related expenses impacted net income, reducing it to $28.1 mln from $32.3 mln in Q2 2024

* REVENUE INCREASE - Net service revenue rose by $30.7 mln to $621.9 mln, driven by growth in healthcare services

* ADJUSTED EBITDA GROWTH - Adjusted EBITDA increased to $80.8 mln, surpassing analyst expectations, attributed to operational efficiencies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.54 $1.33

Adjusted (10

EPS Analysts

)

Q2 Beat $51.40 $45.20

Adjusted mln mln (7

Net Analysts

Income )

Q2 Net $28.10

Income mln

Q2 Beat $80.80 $71.50

Adjusted mln mln (11

EBITDA Analysts

)

Q2 Net $621.90

Service mln

Revenue

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy."

* Wall Street's median 12-month price target for Amedisys Inc ( AMED ) is $101.00, about 4% above its July 28 closing price of $96.91

* The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)